Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
10,154
archived clinical trials in
Other Indications

Homeopathic Ear Drops for Otitis Media Study
Homeopathic Ear Drops for Children With Otitis Media Study
Status: Enrolling
Updated:  12/31/1969
University of Washington Medical Center-Roosevelt Pediatric Care Center
1382
mi
from
Seattle, WA
Homeopathic Ear Drops for Otitis Media Study
Homeopathic Ear Drops for Children With Otitis Media Study
Status: Enrolling
Updated: 12/31/1969
University of Washington Medical Center-Roosevelt Pediatric Care Center
1382
mi
from
Seattle, WA
Click here to add this to my saved trials
Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
Treatment of Patients With Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen: a Randomized Double-blind Placebo-controlled Cross-over Trial
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
979
mi
from
Winston-Salem, NC
Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
Treatment of Patients With Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen: a Randomized Double-blind Placebo-controlled Cross-over Trial
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
979
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Management of Insomnia in Breast Cancer Patients
Management of Insomnia in Breast Cancer Patients: A Preliminary Pilot Study
Status: Enrolling
Updated:  12/31/1969
Stanford University
1329
mi
from
Stanford, CA
Management of Insomnia in Breast Cancer Patients
Management of Insomnia in Breast Cancer Patients: A Preliminary Pilot Study
Status: Enrolling
Updated: 12/31/1969
Stanford University
1329
mi
from
Stanford, CA
Click here to add this to my saved trials
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Status: Enrolling
Updated:  12/31/1969
Fred Hutch/University of Washington Cancer Consortium
1404
mi
from
Seattle, WA
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Status: Enrolling
Updated: 12/31/1969
Fred Hutch/University of Washington Cancer Consortium
1404
mi
from
Seattle, WA
Click here to add this to my saved trials
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Status: Enrolling
Updated:  12/31/1969
VA Puget Sound Health Care System
1410
mi
from
Seattle, WA
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Status: Enrolling
Updated: 12/31/1969
VA Puget Sound Health Care System
1410
mi
from
Seattle, WA
Click here to add this to my saved trials
Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Comprehensive Cancer Center
974
mi
from
Winston-Salem, NC
Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Comprehensive Cancer Center
974
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children
Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children
Status: Enrolling
Updated:  12/31/1969
Slone Epidemiology Center at Boston University
1444
mi
from
Boston, MA
Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children
Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children
Status: Enrolling
Updated: 12/31/1969
Slone Epidemiology Center at Boston University
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children
Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Boston
1442
mi
from
Boston, MA
Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children
Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Boston
1442
mi
from
Boston, MA
Click here to add this to my saved trials
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
CD34+Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease
Status: Enrolling
Updated:  12/31/1969
New York Medical College
1299
mi
from
Valhalla, NY
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
CD34+Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease
Status: Enrolling
Updated: 12/31/1969
New York Medical College
1299
mi
from
Valhalla, NY
Click here to add this to my saved trials
Role of Skeletal Muscle Nitric Oxide Production in Age-related Fatigue and Fatigability
Role of Skeletal Muscle Nitric Oxide Production in Age-related Fatigue and Fatigability
Status: Enrolling
Updated:  12/31/1969
University of Texas Medical Branch
607
mi
from
Galveston, TX
Role of Skeletal Muscle Nitric Oxide Production in Age-related Fatigue and Fatigability
Role of Skeletal Muscle Nitric Oxide Production in Age-related Fatigue and Fatigability
Status: Enrolling
Updated: 12/31/1969
University of Texas Medical Branch
607
mi
from
Galveston, TX
Click here to add this to my saved trials
Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome
A Double-Blind, Placebo-Controlled, Multi-Center, Randomized Trial of the Safety and Efficacy of Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velo-Cardio-Facial Syndrome
Status: Enrolling
Updated:  12/31/1969
VCFS International Center
1194
mi
from
Syracuse, NY
Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome
A Double-Blind, Placebo-Controlled, Multi-Center, Randomized Trial of the Safety and Efficacy of Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velo-Cardio-Facial Syndrome
Status: Enrolling
Updated: 12/31/1969
VCFS International Center
1194
mi
from
Syracuse, NY
Click here to add this to my saved trials
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated:  12/31/1969
Arizona Burn Center at Maricopa Integrated Health Systems
848
mi
from
Phoenix, AZ
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated: 12/31/1969
Arizona Burn Center at Maricopa Integrated Health Systems
848
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated:  12/31/1969
University of California Davis Regional Burn Center
1283
mi
from
Sacramento, CA
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated: 12/31/1969
University of California Davis Regional Burn Center
1283
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated:  12/31/1969
The Burn Center at Washington Hospital Center
1127
mi
from
Washington,
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated: 12/31/1969
The Burn Center at Washington Hospital Center
1127
mi
from
Washington,
Click here to add this to my saved trials
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated:  12/31/1969
Shands Burn Center at University of Florida
1047
mi
from
Gainesville, FL
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated: 12/31/1969
Shands Burn Center at University of Florida
1047
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated:  12/31/1969
Tampa General Hospital
1117
mi
from
Tampa, FL
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated: 12/31/1969
Tampa General Hospital
1117
mi
from
Tampa, FL
Click here to add this to my saved trials
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated:  12/31/1969
Indiana University - Richard M. Fairbanks Burn Center at Wishard Memorial Hospital
643
mi
from
Indianapolis, IN
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated: 12/31/1969
Indiana University - Richard M. Fairbanks Burn Center at Wishard Memorial Hospital
643
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated:  12/31/1969
NC Jaycee Burn Center at University of NC at Chapel Hill
1038
mi
from
Chapel Hill, NC
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated: 12/31/1969
NC Jaycee Burn Center at University of NC at Chapel Hill
1038
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
979
mi
from
Winston-Salem, NC
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
979
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated:  12/31/1969
University of Tennessee Medical Center
467
mi
from
Memphis, TN
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated: 12/31/1969
University of Tennessee Medical Center
467
mi
from
Memphis, TN
Click here to add this to my saved trials
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated:  12/31/1969
USAISR
574
mi
from
Fort Sam Houston, TX
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated: 12/31/1969
USAISR
574
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated:  12/31/1969
Texas Tech University Health Sciences Center
367
mi
from
Lubbock, TX
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated: 12/31/1969
Texas Tech University Health Sciences Center
367
mi
from
Lubbock, TX
Click here to add this to my saved trials
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University Health System- Evans Haynes Burn Center
1113
mi
from
Richmond, VA
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University Health System- Evans Haynes Burn Center
1113
mi
from
Richmond, VA
Click here to add this to my saved trials
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias
Status: Enrolling
Updated:  12/31/1969
University of Maryland Greenebaum Cancer Center
1148
mi
from
Baltimore, MD
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias
Status: Enrolling
Updated: 12/31/1969
University of Maryland Greenebaum Cancer Center
1148
mi
from
Baltimore, MD
Click here to add this to my saved trials
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias
Status: Enrolling
Updated:  12/31/1969
University of Chicago Comprehensive Cancer Center
610
mi
from
Chicago, IL
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias
Status: Enrolling
Updated: 12/31/1969
University of Chicago Comprehensive Cancer Center
610
mi
from
Chicago, IL
Click here to add this to my saved trials
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University-Sidney Kimmel Cancer Center
1149
mi
from
Baltimore, MD
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University-Sidney Kimmel Cancer Center
1149
mi
from
Baltimore, MD
Click here to add this to my saved trials
Herbal Lollipops on Oral Bacterial Levels and DMFT/Dmft Scores of Children With Asthma Using Inhalers
Effects of Herbal Lollipops on Streptococcus Mutans Levels and the Dental Caries Experience of Children With Asthma Taking beta2-adrenergic Agonist Drugs
Status: Enrolling
Updated:  12/31/1969
University of Nebraska Medical Center, Pediatric Dentistry Residency
259
mi
from
Omaha, NE
Herbal Lollipops on Oral Bacterial Levels and DMFT/Dmft Scores of Children With Asthma Using Inhalers
Effects of Herbal Lollipops on Streptococcus Mutans Levels and the Dental Caries Experience of Children With Asthma Taking beta2-adrenergic Agonist Drugs
Status: Enrolling
Updated: 12/31/1969
University of Nebraska Medical Center, Pediatric Dentistry Residency
259
mi
from
Omaha, NE
Click here to add this to my saved trials
Topical Radial Artery Vasodilation
The Effect of Topical Administration of Lidocaine/Nitroglycerin Combination Versus Placebo on Radial Artery Access in Patients Undergoing Cardiac Catheterization Via the Radial Artery
Status: Enrolling
Updated:  12/31/1969
University of California, San Francisco Medical Center
1343
mi
from
San Francisco, CA
Topical Radial Artery Vasodilation
The Effect of Topical Administration of Lidocaine/Nitroglycerin Combination Versus Placebo on Radial Artery Access in Patients Undergoing Cardiac Catheterization Via the Radial Artery
Status: Enrolling
Updated: 12/31/1969
University of California, San Francisco Medical Center
1343
mi
from
San Francisco, CA
Click here to add this to my saved trials
Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS
A Phase I Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1001 (L-Grb-2 Antisense Oligonucleotide) in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Philadelphia Chromosome Positive Chronic Myelogenous Leukemia, or Acute Lymphoblastic Leukemia, and Myelodysplastic Syndrome
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
572
mi
from
Houston, TX
Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS
A Phase I Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1001 (L-Grb-2 Antisense Oligonucleotide) in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Philadelphia Chromosome Positive Chronic Myelogenous Leukemia, or Acute Lymphoblastic Leukemia, and Myelodysplastic Syndrome
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
572
mi
from
Houston, TX
Click here to add this to my saved trials
Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia
Phase II Study of Bortezomib (VELCADE) for the Treatment of Relapsed or Refractory T-cell Prolymphocytic Leukemia
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
1329
mi
from
Stanford, CA
Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia
Phase II Study of Bortezomib (VELCADE) for the Treatment of Relapsed or Refractory T-cell Prolymphocytic Leukemia
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
1329
mi
from
Stanford, CA
Click here to add this to my saved trials
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Alabama
684
mi
from
Birmingham, AL
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Alabama
684
mi
from
Birmingham, AL
Click here to add this to my saved trials
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated:  12/31/1969
University of South Alabama
734
mi
from
Mobile, AL
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated: 12/31/1969
University of South Alabama
734
mi
from
Mobile, AL
Click here to add this to my saved trials
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated:  12/31/1969
Providence Alaska Medical Center
2732
mi
from
Anchorage, AK
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated: 12/31/1969
Providence Alaska Medical Center
2732
mi
from
Anchorage, AK
Click here to add this to my saved trials
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated:  12/31/1969
Cardon Children's Medical Center
844
mi
from
Mesa, AZ
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated: 12/31/1969
Cardon Children's Medical Center
844
mi
from
Mesa, AZ
Click here to add this to my saved trials
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated:  12/31/1969
Phoenix Children's Hospital
849
mi
from
Phoenix, AZ
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated: 12/31/1969
Phoenix Children's Hospital
849
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated:  12/31/1969
University of Arizona Medical Center University Campus
833
mi
from
Tucson, AZ
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated: 12/31/1969
University of Arizona Medical Center University Campus
833
mi
from
Tucson, AZ
Click here to add this to my saved trials
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated:  12/31/1969
Arkansas Children's Hospital
372
mi
from
Little Rock, AR
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated: 12/31/1969
Arkansas Children's Hospital
372
mi
from
Little Rock, AR
Click here to add this to my saved trials
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated:  12/31/1969
City of Hope Comprehensive Cancer Center
1152
mi
from
Duarte, CA
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated: 12/31/1969
City of Hope Comprehensive Cancer Center
1152
mi
from
Duarte, CA
Click here to add this to my saved trials
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated:  12/31/1969
Loma Linda University Medical Center
1114
mi
from
Loma Linda, CA
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated: 12/31/1969
Loma Linda University Medical Center
1114
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated:  12/31/1969
Miller Children's and Women's Hospital Long Beach
1171
mi
from
Long Beach, CA
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated: 12/31/1969
Miller Children's and Women's Hospital Long Beach
1171
mi
from
Long Beach, CA
Click here to add this to my saved trials
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated:  12/31/1969
Childrens Hospital Los Angeles
1169
mi
from
Los Angeles, CA
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated: 12/31/1969
Childrens Hospital Los Angeles
1169
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center
1168
mi
from
Los Angeles, CA
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
1168
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated:  12/31/1969
Mattel Children's Hospital at UCLA
1177
mi
from
Los Angeles, CA
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated: 12/31/1969
Mattel Children's Hospital at UCLA
1177
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Central California
1215
mi
from
Madera, CA
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Central California
1215
mi
from
Madera, CA
Click here to add this to my saved trials
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated:  12/31/1969
Children's Hospital and Research Center Oakland
1330
mi
from
Oakland, CA
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated: 12/31/1969
Children's Hospital and Research Center Oakland
1330
mi
from
Oakland, CA
Click here to add this to my saved trials
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-Oakland
1327
mi
from
Oakland, CA
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-Oakland
1327
mi
from
Oakland, CA
Click here to add this to my saved trials
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Orange County
1154
mi
from
Orange, CA
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Orange County
1154
mi
from
Orange, CA
Click here to add this to my saved trials
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated:  12/31/1969
Lucile Packard Children's Hospital Stanford University
1329
mi
from
Palo Alto, CA
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated: 12/31/1969
Lucile Packard Children's Hospital Stanford University
1329
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated:  12/31/1969
University of California-Davis Comprehensive Cancer Ctr
1281
mi
from
Sacramento, CA
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated: 12/31/1969
University of California-Davis Comprehensive Cancer Ctr
1281
mi
from
Sacramento, CA
Click here to add this to my saved trials
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated:  12/31/1969
Rady Children's Hospital - San Diego
1140
mi
from
San Diego, CA
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Status: Enrolling
Updated: 12/31/1969
Rady Children's Hospital - San Diego
1140
mi
from
San Diego, CA
Click here to add this to my saved trials